Stock analysts at StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Get Free Report) in a research note issued on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
MediciNova Stock Performance
Shares of NASDAQ MNOV opened at $1.44 on Tuesday. The stock’s 50-day simple moving average is $1.37 and its 200-day simple moving average is $1.42. The firm has a market capitalization of $70.63 million, a PE ratio of -8.47 and a beta of 0.72. MediciNova has a fifty-two week low of $1.26 and a fifty-two week high of $2.66.
MediciNova (NASDAQ:MNOV – Get Free Report) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). On average, sell-side analysts forecast that MediciNova will post -0.23 earnings per share for the current fiscal year.
Institutional Investors Weigh In On MediciNova
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Stories
- Five stocks we like better than MediciNova
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- The 3 Best Blue-Chip Stocks to Buy Now
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- 5 discounted opportunities for dividend growth investors
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.